scispace - formally typeset
T

Tomoki Aoyama

Researcher at Kyoto University

Publications -  295
Citations -  6663

Tomoki Aoyama is an academic researcher from Kyoto University. The author has contributed to research in topics: Osteoarthritis & Knee pain. The author has an hindex of 38, co-authored 277 publications receiving 5378 citations. Previous affiliations of Tomoki Aoyama include American Physical Therapy Association & Industrial Research Institute.

Papers
More filters
Journal ArticleDOI

Prevalence of Sarcopenia in Community-Dwelling Japanese Older Adults

TL;DR: The results suggest that sarcopenia is highly prevalent in community-dwelling Japanese older adults and is related to falls and fear of falling.
Journal ArticleDOI

Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells.

TL;DR: These cell lines, being the first established immortalized clonal cell lines of hMSCs, could provide insights into the mechanisms regulating the early steps of differentiation from undifferentiated MSCs into a specific lineage.
Journal ArticleDOI

Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion.

TL;DR: Results indicated p16INK4A to be a key factor in the regulation of hMSC growth, and careful monitoring of DNA methylation should be considered during the culture of h MSCs, particularly when a prolonged and extended propagation is required.
Journal ArticleDOI

Reliability and validity of gait analysis by android-based smartphone.

TL;DR: This study indicates that the smartphone with gait analysis application used in this study has the capacity to quantify gait parameters with a degree of accuracy that is comparable to that of the tri-axial accelerometer.
Journal ArticleDOI

Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas

TL;DR: Findings suggest that a humanized antibody against FZD10 might be a promising treatment for patients with tumors that overexpress FzD10; minimal or no adverse reactions would be expected because FZd10 protein is not abundant in vital organs.